Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells

Pharmacological Reports

Volumn 66, Issue 1, 2014, Pages 130-136

  Walczak, Katarzyna ^a,b   Deneka Hannemann, Sylwia ^c   Jarosz, Bozena ^a   Zgrajka, Wojciech ^b   Stoma, Filip ^a   Trojanowski, Tomasz ^a   Turski, Waldemar A ^a,b   Rzeski, Wojciech ^b,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Glioma; Glutamate antagonists; Kynurenic acid; Proliferation

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; DIZOCILPINE; GLUTAMIC ACID; KYNURENIC ACID; TEMOZOLOMIDE; BENZODIAZEPINE DERIVATIVE;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRAIN HISTOLOGY; BRDU ASSAY; CANCER THERAPY; CELL MOTION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MIDDLE AGED; MIGRATION INHIBITION; MTT ASSAY; BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; BENZODIAZEPINES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GLIOBLASTOMA; GLUTAMIC ACID; HUMANS; KYNURENIC ACID; MALE; MIDDLE AGED;

EID: 84899637029     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2013.06.007     Document Type: Article

References (43)

1. Baran H, Cairns N, Lubec B, Lubec G. Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syn-drome. Life Sci 1996;58:1891-9 (Pubitemid 26164612)
2. Baran H, Hainfellner JA, Kepplinger B, Mazal PR, Schmid H, Budka H. Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm 2000;107:1127-38
3. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999;106:165-81 (Pubitemid 29137514)
4. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced forma-tion of kynurenic acid. J Neurochem 1990;55:1327-39
5. Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentia-tion in the hippocampus. Nature 1993;361:31-9 (Pubitemid 23020772)
6. Cavalheiro EA, Olney JW. Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci U S A 2001;98:5947-8 (Pubitemid 32488170)
7. Clark AS, Stevens MF, Sansom CE, Schwalbe CH. Anti-tumour imidazotetra-zines. Part XXI: Mitozolomide and temozolomide-probes for the major groove of DNA. Anticancer Drug Des 1990;5:63-88
8. Collingridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat. J Physiol 1983;334:33-46 (Pubitemid 13176081)
9. Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, et al. Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol 2005;25:981-93 (Pubitemid 43154822)
10. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 2010;115:89-97
11. Friedman HS, McLendon RE, Kerby T. DNA mismatch repair and O6-alkylgua-nine-DNA alkyltransferase analysis and response to Temodal in newly diag-nosed malignant glioma. J Clin Oncol 1998;16:3851-7 (Pubitemid 29001538)
12. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX The brain metabolite kynurenic acid inhibits a7 nicotinic receptor activity.nd increases non-a7 nicotinic receptor expression: physiopathological implications. J Neurosci.2001. 21.7463-73
13. Hotta T, Saito Y, Fujita H, Mikami T, Kurisu K, Kiya K, et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994;21:135-40
14. Jennings MT, Frenchman M, Shehab T, Johnson MD, Creasy J, LaPorte K, et al. Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 1995;10:37-45
15. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histologic correlations of computed tomography-and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450-9 (Pubitemid 17084816)
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon: IARC; 2007
17. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99:467-73 (Pubitemid 37040405)
18. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999;399:A7-14
19. Litchfield JT, Wilcoxon FA. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99-113
20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109 (Pubitemid 47103521)
21. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine gluta-mate signaling promotes glioma cell invasion. Cancer Res 2007;67:9463-71 (Pubitemid 47535936)
22. Markert J, Devita VT, Hellman S, Rosenberg SA, editors. Glioblastoma multi-forme. 1st ed., Sudbury: Jones & Bartlett Publishers; 2005. p. 21-39. chapter 2
23. McNamara JO. Emerging insights into the genesis of epilepsy. Nature 1999;399:A15-22
24. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992;42:1702-6
25. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969;164:719-21
26. Rzeski W, Kocki T, Dybel A, Wejksza K, Zdzisiníska B, Kandefer-SzerszeníM, et al. Demonstration of kynurenine aminotransferases I and II and characteri-zation of kynurenic acid synthesis in cultured cerebral cortical neurons. J Neurosci Res 2005;80:677-82 (Pubitemid 40896188)
27. Rzeski W, Matysiak J, Kandefer-SzerszeníM. Anticancer, neuroprotective activities and computational studies of 2-amino-1,3,4- thiadiazole based com-pound. Bioorg Med Chem 2007;15:3201-7 (Pubitemid 46484337)
28. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A 2001;98:6372-7 (Pubitemid 32488244)
29. Scharfman HE, Goodman JH, Schwarcz R. Electrophysiological effects of exog-enous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids 2000;19:283-97
30. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002;303:1-10
31. Schwarcz R, Rassoulpour A, Wu H-Q, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001;50:521-30 (Pubitemid 32971883)
32. Stepulak A, Luksch H, Gebhardt C, Uckerman O, Sifringer M, Rzeski W, et al. Expression of glutamate receptors in cancer cell lines. Histochem Cell Biol 2009;132:435-45
33. Stepulak A, Sifringer M, Rzeski W, Brocke K, Gratopp A, Pohl EE, et al. AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther 2007;6:1908-15 (Pubitemid 351590403)
34. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, et al. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A 2005;102:15605-10 (Pubitemid 41528103)
35. Takano T, Lin JHC, Arcuindo G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med 2001;7:1010-5 (Pubitemid 32937380)
36. Turski L, Cavalheiro EA, Schoepp DD. Excitatory amino acids: ten years later. Amsterdam: IOS Press; 2001
37. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell Jr. WO, Schwarcz R. Identification and quantification of kynurenic acid in human brain tissue. Brain Res 1988;454:164-9
38. Walczak K, Dabrowski W, Langner E, Zgrajka W, Piat J, Kocki T, et al. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol 2011;46:903-12
39. Walczak K, Zurawska M, Kiś J, Starownik R, Zgrajka W, Bar K, et al. Kynurenic acid in human renal cell carcinoma: its antiproliferative and antimigrative action on Caki-2 cells. Amino Acids 2012;43:1663-70
40. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006;281:22021-28 (Pubitemid 44181906)
41. Wejksza K, Rzeski W, Okuno E, Kandefer-Szerszen M, Albrecht J, Turski WA. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in OLN-93 oligodendrocyte cell line. Neurochem Res 2005;30:963-8 (Pubitemid 41570031)
42. Wejksza K, Rzeski W, Turski WA, Hilgier W, Dybel A, Albrecht J. Ammonia at pathophysiologically relevant concentrations activates kynurenic acid syn-thesis in cultured astrocytes and neurons. Neurotoxicology 2006;27:615-8
43. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999;59:4383-91. (Pubitemid 29418758)